Skip to main content

Articles

Page 2 of 3

  1. For many promising target cells (e.g.: haematopoeitic progenitors), the susceptibility to standard adeno-associated viral (AAV) vectors is low. Advancements in vector development now allows the generation of t...

    Authors: Marius Stiefelhagen, Leopold Sellner, Jürgen A Kleinschmidt, Anna Jauch, Stephanie Laufs, Frederik Wenz, W Jens Zeller, Stefan Fruehauf and Marlon R Veldwijk
    Citation: Genetic Vaccines and Therapy 2008 6:12
  2. Application of plasmid DNA for immunization of food-producing animals established new standards of food safety. The addition of foreign products e.g. pDNA into the food chain should be carefully examined to en...

    Authors: Petr Orság, Veronika Kvardová, Milan Raška, Andrew D Miller, Miroslav Ledvina and Jaroslav Turánek
    Citation: Genetic Vaccines and Therapy 2008 6:11
  3. In situ production of a secreted therapeutic protein is one of the major gene therapy applications. Nevertheless, the plasmatic secretion peak of transgenic protein may be deleterious in many gene therapy applica...

    Authors: Emmanuelle E Fabre, Pascal Bigey, Yves Beuzard, Daniel Scherman and Emmanuel Payen
    Citation: Genetic Vaccines and Therapy 2008 6:10
  4. Vectors based on adeno-associated virus-8 (AAV8) have shown efficiency and efficacy for liver-directed gene therapy protocols following intravascular injection, particularly in relation to haemophilia gene the...

    Authors: Tracey Graham, Jenny McIntosh, Lorraine M Work, Amit Nathwani and Andrew H Baker
    Citation: Genetic Vaccines and Therapy 2008 6:9
  5. Solid tumours account for 90% of all cancers. Gene therapy represents a potential new modality for their treatment. Up to now, several approaches have been developed, but the most efficient ones are the viral ...

    Authors: Ming Q Wei, Ruimei Ren, David Good and Jozef Anné
    Citation: Genetic Vaccines and Therapy 2008 6:8
  6. Asthma is a complex disease, characterized by reversible airway obstruction, hyperresponsiveness and chronic inflammation. Principle pharmacologic treatments for asthma include bronchodilating beta2-agonists a...

    Authors: Xiaoqin Wang, Weidong Xu, Subhra Mohapatra, Xiaoyuan Kong, Xu Li, Richard F Lockey and Shyam S Mohapatra
    Citation: Genetic Vaccines and Therapy 2008 6:7
  7. Bovine herpesvirus 4 (BoHV-4) is a gamma-herpesvirus with no clear disease association. A recombinant BoHV-4 (BoHV-4EGFPΔTK) expressing Green Fluorescent Protein (EGFP), was successfully used to infect F98 rat...

    Authors: Marco Redaelli, Andrea Cavaggioni, Carla Mucignat-Caretta, Sandro Cavirani, Antonio Caretta and Gaetano Donofrio
    Citation: Genetic Vaccines and Therapy 2008 6:6
  8. It is believed that respiratory mucosal immunization triggers more effective immune protection than parenteral immunization against respiratory infection caused by viruses and intracellular bacteria. Such unde...

    Authors: Daniela Damjanovic, Xizhong Zhang, Jingyu Mu, Maria Fe Medina and Zhou Xing
    Citation: Genetic Vaccines and Therapy 2008 6:5
  9. Tattooing is one of a number of DNA delivery methods which results in an efficient expression of an introduced gene in the epidermal and dermal layers of the skin. The tattoo procedure causes many minor mechan...

    Authors: Dana Pokorna, Ivonne Rubio and Martin Müller
    Citation: Genetic Vaccines and Therapy 2008 6:4
  10. A number of reports have demonstrated that rodents immunized with DNA vaccines can produce antibodies and cellular immune responses presenting a long-lasting protective immunity. These findings have attracted ...

    Authors: Luís H Franco, Pryscilla F Wowk, Célio L Silva, Ana PF Trombone, Arlete AM Coelho-Castelo, Constance Oliver, Maria C Jamur, Edson L Moretto and Vânia LD Bonato
    Citation: Genetic Vaccines and Therapy 2008 6:3
  11. Early prostate adenocarcinoma can be diagnosed through seric prostate-specific antigen (PSA) screenings. However, a fraction of patients progress to an incurable metastatic disease. Therefore, novel therapies ...

    Authors: Juliana M Sousa-Canavez, Flavio C Canavez, Kátia RM Leite and Luiz H Camara-Lopes
    Citation: Genetic Vaccines and Therapy 2008 6:2
  12. Ischemic brain injury and epilepsy are common neurodegenerative diseases caused by excitotoxicity. Their pathogenesis includes microglial production of inflammatory cytokines. Our studies were designed to exam...

    Authors: Jennifer M Laing and Laure Aurelian
    Citation: Genetic Vaccines and Therapy 2008 6:1
  13. Adeno-associated virus (AAV) has shown great promise as a gene transfer vector. However, the incubation time needed to attain significant levels of gene expression is often too long for some clinical applicati...

    Authors: Lourdes M Andino, Thomas J Conlon, Stacy L Porvasnik, Sanford L Boye, William W Hauswirth and Alfred S Lewin
    Citation: Genetic Vaccines and Therapy 2007 5:13
  14. Vaccination of neonates is generally difficult due to the immaturity of the immune system and consequent higher susceptibility to tolerance induction. Genetic immunization has been described as an alternative ...

    Authors: Ana Cláudia Pelizon, Douglas R Martins, Sofia FG Zorzella, Ana Paula F Trombone, Júlio CC Lorenzi, Robson F Carvalho, Izaíra T Brandão, Arlete AM Coelho-Castelo, Célio L Silva and Alexandrina Sartori
    Citation: Genetic Vaccines and Therapy 2007 5:12
  15. Polyethylenimine (PEI) is one of the most efficient and versatile non-viral vectors available for gene delivery. Despite many advantages over viral vectors, PEI is still limited by lower transfection efficienc...

    Authors: Stephen R Doyle and Chee Kai Chan
    Citation: Genetic Vaccines and Therapy 2007 5:11
  16. The presence of CAR in diverse tumor types is heterogeneous with implications in tumor transduction efficiency in the context of adenoviral mediated cancer gene therapy. Preliminary studies suggest that CAR tr...

    Authors: Blanca Segura-Pacheco, Berenice Avalos, Edgar Rangel, Dora Velazquez and Gustavo Cabrera
    Citation: Genetic Vaccines and Therapy 2007 5:10
  17. This study aimed to demonstrate that microspheres, used as delivery vehicle of DNA-Hsp65/TDM [plasmid DNA encoding heat shock protein 65 (Hsp65) coencapsulated with trehalose dimycolate (TDM) into PLGA microsp...

    Authors: Ana Paula F Trombone, Celio L Silva, Luciana P Almeida, Rogerio S Rosada, Karla M Lima, Constance Oliver, Maria C Jamur and Arlete AM Coelho-Castelo
    Citation: Genetic Vaccines and Therapy 2007 5:9
  18. Safe and efficient vector systems for delivering antigens or immunomodulatory molecules to dendritic cells (DCs), T lymphocytes or both are considered effective means of eliciting adaptive immune responses and...

    Authors: Mauro Pistello, Laura Vannucci, Alessia Ravani, Francesca Bonci, Flavia Chiuppesi, Barbara Del Santo, Giulia Freer and Mauro Bendinelli
    Citation: Genetic Vaccines and Therapy 2007 5:8
  19. Vaccines are considered by many to be one of the most successful medical interventions against infectious diseases. But many significant obstacles remain, such as optimizing DNA vaccines for use in humans or l...

    Authors: Eduardo DC Gonçalves, Vânia Luiza D Bonato, Denise M da Fonseca, Edson G Soares, Izaíra T Brandão, Ana Paula M Soares and Célio L Silva
    Citation: Genetic Vaccines and Therapy 2007 5:7
  20. Respiratory syncytial virus (RSV) causes severe bronchiolitis and is a risk factor for asthma. Since there is no commercially available vaccine against RSV, a short interfering RNA against the RSV-NS1gene (siN...

    Authors: Xiaoyuan Kong, Weidong Zhang, Richard F Lockey, Alexander Auais, Giovanni Piedimonte and Shyam S Mohapatra
    Citation: Genetic Vaccines and Therapy 2007 5:4
  21. For reasons of efficiency Escherichia coli is used today as the microbial factory for production of plasmid DNA vaccines. To avoid hazardous antibiotic resistance genes and endotoxins from plasmid systems used no...

    Authors: Gregers J Gram, Anders Fomsgaard, Mette Thorn, Søren M Madsen and Jacob Glenting
    Citation: Genetic Vaccines and Therapy 2007 5:3
  22. The great challenges for researchers working in the field of vaccinology are optimizing DNA vaccines for use in humans or large animals and creating effective single-dose vaccines using appropriated controlled...

    Authors: Lúcia de Paula, Célio L Silva, Daniela Carlos, Camila Matias-Peres, Carlos A Sorgi, Edson G Soares, Patrícia RM Souza, Carlos RZ Bladés, Fábio CS Galleti, Vânia LD Bonato, Eduardo DC Gonçalves, Érika VG Silva and Lúcia H Faccioli
    Citation: Genetic Vaccines and Therapy 2007 5:2
  23. Mucopolysaccharidosis type IIIA (MPS IIIA) is the most common of the mucopolysaccharidoses. The disease is caused by a deficiency of the lysosomal enzyme sulphamidase and results in the storage of the glycosam...

    Authors: Donald S Anson, Chantelle McIntyre, Belinda Thomas, Rachel Koldej, Enzo Ranieri, Ainslie Roberts, Peter R Clements, Kylie Dunning and Sharon Byers
    Citation: Genetic Vaccines and Therapy 2007 5:1
  24. The rapid degradation of ribonucleic acids (RNA) by ubiquitous ribonucleases limits the efficacy of new therapies based on RNA molecules. Therefore, our aim was to characterize the natural ribonuclease activit...

    Authors: Jochen Probst, Sonja Brechtel, Birgit Scheel, Ingmar Hoerr, Günther Jung, Hans-Georg Rammensee and Steve Pascolo
    Citation: Genetic Vaccines and Therapy 2006 4:4
  25. Duchenne muscular dystrophy is a fatal genetic disorder caused by dystrophin gene mutations that result in premature termination of translation and the absence of functional protein. Despite the primary dystro...

    Authors: Abbie M Fall, Russell Johnsen, Kaite Honeyman, Pat Iversen, Susan Fletcher and Stephen D Wilton
    Citation: Genetic Vaccines and Therapy 2006 4:3
  26. Published data indicate that formulation of pDNA with cationic lipids could greatly enhance the response to a pDNA vaccine in larger mammals. The present work tested the influence of several pDNA:cationic lipi...

    Authors: Michal Margalith and Adrián Vilalta
    Citation: Genetic Vaccines and Therapy 2006 4:2
  27. In order to assess a new strategy of DNA vaccine for a more complete understanding of its action in immune response, it is important to determine the in vivo biodistribution fate and antigen expression. In previo...

    Authors: AAM Coelho-Castelo, AP Trombone, RS Rosada, RR Santos Jr, VLD Bonato, A Sartori and CL Silva
    Citation: Genetic Vaccines and Therapy 2006 4:1
  28. Gene targeting in vivo provides a potentially powerful method for gene analysis and gene therapy. In order to sensitively detect and accurately measure designed sequence changes, we have used a transgenic mouse s...

    Authors: Asami Ino, Yasuhiro Naito, Hiroyuki Mizuguchi, Naofumi Handa, Takao Hayakawa and Ichizo Kobayashi
    Citation: Genetic Vaccines and Therapy 2005 3:8
  29. Several studies have shown that cell-mediated immune responses play a crucial role in controlling viral replication. As such, a candidate SARS vaccine should elicit broad CD8+ T-cell immune responses. Several ...

    Authors: Ali Azizi, Susan Aucoin, Helina Tadesse, Rita Frost, Masoud Ghorbani, Catalina Soare, Turaya Naas and Francisco Diaz-Mitoma
    Citation: Genetic Vaccines and Therapy 2005 3:7
  30. Anti-tumor vaccines targeting the entire tumor antigen repertoire represent an attractive immunotherapeutic approach. In the context of a phase I/II clinical trial, we vaccinated metastatic melanoma patients w...

    Authors: Jean-Philippe Carralot, Benjamin Weide, Oliver Schoor, Jochen Probst, Birgit Scheel, Regina Teufel, Ingmar Hoerr, Claus Garbe, Hans-Georg Rammensee and Steve Pascolo
    Citation: Genetic Vaccines and Therapy 2005 3:6
  31. Lung cancer has emerged as a leading cause of cancer death in the world. Non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Current therapies are ineffective, thus new approaches are n...

    Authors: Min Zhang, Xin Zhang, Chun-Xue Bai, Xian-Rang Song, Jie Chen, Lei Gao, Jie Hu, Qun-Ying Hong, Malcolm J West and Ming Q Wei
    Citation: Genetic Vaccines and Therapy 2005 3:5
  32. The production of cell-based cancer vaccines by gene vectors encoding proteins that stimulate the immune system has advanced rapidly in model systems. We sought to develop non-viral transfection methods that c...

    Authors: Jill A Gershan, Bryon D Johnson, James Weber, Dennis W Schauer, Natalia Natalia, Stephanie Behnke, Karen Burns, Kelly W Maloney, Anne B Warwick and Rimas J Orentas
    Citation: Genetic Vaccines and Therapy 2005 3:4
  33. Previously, antigens expressed from DNA vaccines have been fused to the VP22 protein from Herpes Simplex Virus type I in order to improve efficacy. However, the immune enhancing mechanism of VP22 is poorly und...

    Authors: Stuart D Perkins, Helen C Flick-Smith, Helen S Garmory, Angela E Essex-Lopresti, Freda K Stevenson and Robert J Phillpotts
    Citation: Genetic Vaccines and Therapy 2005 3:3
  34. We have constructed and evaluated the utility of a helper-dependent virus vector system that is derived from Human Cytomegalovirus (HCMV). This vector is based on the herpes simplex virus (HSV) amplicon system...

    Authors: Kutubuddin Mahmood, Mark N Prichard, Gregory M Duke, George W Kemble and Richard R Spaete
    Citation: Genetic Vaccines and Therapy 2005 3:1
  35. Targeted gene transfection remains a crucial issue to permit the real development of genetic therapy. As such, in vivo targeted transfection of specific subsets of hematopoietic stem cells might help to sustain h...

    Authors: Alain Chapel, Olivier Deas, Morad Bensidhoum, Sabine François, Moubarak Mouiseddine, Pascal Poncet, Antoine Dürrbach, Jocelyne Aigueperse, Patrick Gourmelon, Norbert C Gorin, François Hirsch and Dominique Thierry
    Citation: Genetic Vaccines and Therapy 2004 2:16
  36. Modulation of the immune system by genetically modified lymphoma cell vaccines is of potential therapeutic value in the treatment of B cell lymphoma. However, the anti-tumor effect of any single immunogene tra...

    Authors: Oliver Ebert, Dorothee Wilbert, Peter Buttgereit, Carsten Ziske, Dimitri Flieger and Ingo GH Schmidt-Wolf
    Citation: Genetic Vaccines and Therapy 2004 2:15
  37. The establishment of efficient gene delivery to target human tissue is a major obstacle for transition of gene therapy from the pre-clinical phases to the clinic. The poor long-term patency rates for coronary ...

    Authors: Lorraine M Work, Paul N Reynolds and Andrew H Baker
    Citation: Genetic Vaccines and Therapy 2004 2:14
  38. Modulation of the immune system by genetically modified immunological effector cells is of potential therapeutic value in the treatment of malignancies. Interleukin-2 (IL-2) is a crucial cytokine which induces...

    Authors: Srinivas Nagaraj, Carsten Ziske and Ingo GH Schmidt-Wolf
    Citation: Genetic Vaccines and Therapy 2004 2:12
  39. Viral promoters are used in mammalian expression vectors because they generally have strong activity in a wide variety of cells of differing tissues and species.

    Authors: Jerome S Harms, Kurt A Eakle, Lillian S Kuo, Robert D Bremel and Gary A Splitter
    Citation: Genetic Vaccines and Therapy 2004 2:11
  40. A vaccine that elicits durable, powerful anti-HIV immunity remains an elusive goal. In these studies we tested whether multiple treatments with viral vector-delivered HIV envelope antigen (gp120), with and wit...

    Authors: Hayley J McKee, Patricia Y T'sao, Maria Vera, Puri Fortes and David S Strayer
    Citation: Genetic Vaccines and Therapy 2004 2:10
  41. Retroviral vector-mediated gene transfer has been central to the development of gene therapy. Retroviruses have several distinct advantages over other vectors, especially when permanent gene transfer is the pr...

    Authors: Donald S Anson
    Citation: Genetic Vaccines and Therapy 2004 2:9
  42. The need for safe and effective treatment of dengue virus (DEN), a class A agent that causes dengue hemorrhagic fever/dengue shock syndrome, has been a critical global priority. An effective vaccine for DEN is...

    Authors: Weidong Zhang, Rajeswari Singam, Gary Hellermann, Xiaoyuan Kong, Homero San Juan, Richard F Lockey, Shuen-Ju Wu, Kevin Porter and Shyam S Mohapatra
    Citation: Genetic Vaccines and Therapy 2004 2:8
  43. Suicide gene therapy employing the prodrug activating system Herpes simplex virus type 1 thymidine kinase (HSV-TK)/ ganciclovir (GCV) has proven to be effective in killing experimental brain tumors. In contras...

    Authors: Ariane Söling, Christian Theiß, Stephanie Jungmichel and Nikolai G Rainov
    Citation: Genetic Vaccines and Therapy 2004 2:7
  44. Although lentiviral vectors have been widely used for in vitro and in vivo gene therapy researches, there have been few studies systematically examining various conditions that may affect the determination of the...

    Authors: Bing Zhang, Pat Metharom, Howard Jullie, Kay AO Ellem, Geoff Cleghorn, Malcolm J West and Ming Q Wei
    Citation: Genetic Vaccines and Therapy 2004 2:6
  45. In humans, overproduction of apolipoprotein B (apoB) is positively associated with premature coronary artery diseases. To reduce the levels of apoB mRNA, we have designed an apoB mRNA-specific hammerhead riboz...

    Authors: Shumei Zhong, Shihua Sun and Ba-Bie Teng
    Citation: Genetic Vaccines and Therapy 2004 2:5